Hormone Therapy Boosts Semaglutide Weight Loss in Menopausal Women, Study Finds

For midlife women managing both menopausal symptoms and weight gain, a new clinical analysis reveals a biological synergy between two of the most prescribed drug classes in the United States. Replacing declining estrogen with hormone therapy appears to prime the body to respond better to semaglutide, the active ingredient in Wegovy and Ozempic.[2][6]

The findings, presented at the 2026 Annual Meeting of The Menopause Society in San Diego, offer the first large-scale evidence that a patient's hormonal status directly influences how well anti-obesity medications work. While GLP-1 drugs reliably suppress appetite, the metabolic slowdown and fat redistribution that accompany menopause can blunt their efficacy.[2][3]

Researchers from the Mayo Clinic analyzed electronic health records from nearly 3,900 women aged 45 and older. The cohort had an average age of 57 and a baseline body mass index of 36, representing a demographic that frequently struggles with midlife metabolic changes.[3][6]

Among the roughly 2,400 women taking semaglutide, those who concurrently used oral or transdermal hormone therapy lost significantly more weight. By the end of the 15-month observation period, hormone therapy users had lost an average of 11.9 percent of their total body weight, compared to 10.9 percent for those taking semaglutide alone.[3]

Accelerated weight loss thresholds

Translated to pounds, women combining the treatments lost an average of 25 pounds, while those on semaglutide alone lost 23 pounds. The difference became even more pronounced at higher weight-loss thresholds, suggesting that estrogen helps a subset of patients achieve exceptional results.[6]

Twenty-two percent of the women combining semaglutide with hormone therapy shed at least a fifth of their body weight, compared to just 18 percent of the non-hormone group. Furthermore, 13 percent of the hormone therapy users reached a 25 percent weight-loss milestone, outpacing the 10 percent of non-users who did the same.[3]

"Our earlier, smaller studies showed an association between hormone therapy use and greater weight loss in postmenopausal women, and the fact that we see the same signal in a larger, independent cohort should not be overlooked," said lead study author Dr. Regina Castaneda, a postdoctoral research fellow at Mayo Clinic Florida.[6]

The estrogen metabolic link

The transition into menopause triggers a cascade of metabolic changes that make weight loss uniquely difficult. As ovarian estrogen production drops, women typically experience a decrease in lean muscle mass and an increase in visceral fat—the metabolically active fat stored deep within the abdomen.[2][5]

This hormonal shift alters how the body processes glucose and stores energy, often leading to insulin resistance. When women in this demographic take a GLP-1 receptor agonist, the drug must work against a biological environment that is actively promoting fat retention.[2]

Hormone replacement therapy, which typically involves estrogen with or without progesterone, reverses some of this metabolic disadvantage. By restoring estrogen levels, the therapy may improve insulin sensitivity and help preserve the lean muscle required to maintain a healthy resting metabolic rate.[2][3]

"It is also biologically plausible, given preclinical data suggesting a potential synergistic effect between estrogen and GLP-1 signaling," Castaneda noted, pointing to the underlying cellular mechanisms that govern energy balance.[6]

Diverging drug responses

While the synergy was clear for semaglutide, the researchers found a different pattern when they analyzed the 1,500 women taking tirzepatide, the active ingredient in Mounjaro and Zepbound. Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors.[2][3]

Women taking tirzepatide alongside hormone therapy saw a modest initial boost, losing 6.6 percent of their body weight at three months compared to 5.9 percent for those not on hormones. However, that advantage vanished over time.[2]

By the 15-month mark, there was no statistically significant difference in weight loss between the two tirzepatide groups. Both cohorts lost an average of roughly 35 pounds, outperforming the semaglutide users overall, regardless of their hormonal status.[3][6]

Endocrinologists suspect that tirzepatide's dual-action mechanism may simply max out the body's weight-loss pathways on its own, leaving no room for estrogen to provide an additional metabolic boost. Alternatively, the GIP receptor activation might bypass the specific metabolic bottlenecks that estrogen helps clear for semaglutide.[3]

Clinical takeaways for patients

For women navigating the menopausal transition, the findings provide a reassuring layer of data for those already managing severe symptoms. Hormone therapy remains the most effective treatment for vasomotor symptoms like hot flashes and night sweats, which affect up to 75 percent of postmenopausal women.[3]

If a patient requires hormone therapy for quality of life and also meets the clinical criteria for a GLP-1 medication, the two treatments can be safely and effectively combined. The added weight-loss benefit on semaglutide serves as a secondary advantage rather than a primary reason to prescribe hormones.[2][3]

Medical guidelines remain firm that hormone therapy should not be initiated strictly for weight management. The risks and benefits of systemic estrogen—which can include cardiovascular and cancer considerations depending on a patient's age and medical history—must be weighed against the severity of their menopausal symptoms.[2][3]

"For a woman who has both bothersome menopausal symptoms and obesity, it may be entirely appropriate to consider both treatments," said Dr. Betul Hatipoglu, Director of the Diabetes and Obesity Center at University Hospitals Cleveland Medical Center, who reviewed the findings.[2]

"But I would not recommend starting hormone therapy solely to improve the weight-loss response to a GLP-1 medication based on the evidence currently available," Hatipoglu added, emphasizing that obesity treatment must be individualized.[2]

Because the Mayo Clinic analysis was retrospective and observational, it cannot definitively prove that hormone therapy caused the extra weight loss. Women taking hormones might also be more proactive about other health behaviors, such as diet and exercise, which are critical for preserving bone density and muscle mass during rapid weight loss.[2][3]

Future randomized controlled trials will be needed to isolate the exact biological mechanisms at play. Until then, the data confirms that treating the hormonal realities of menopause does not hinder—and may actively help—the pharmacological treatment of obesity.[2][3]